Editas Medicine Q3 net loss narrows
EDIT•Editas Medicine reported a third-quarter net loss of $23.39 million, below the $27.69 million analyst estimate. Collaboration and other R&D revenue was $10.40 million, and the company ended the quarter with $190.2 million in cash and marketable securities.
1. Quarterly results
Editas Medicine’s third-quarter net loss was $23.39 million, compared with an analyst estimate of $27.69 million. Loss per share was $0.15, while collaboration and other research and development revenue was $10.40 million, driven by milestone payments from a strategic partner.
2. Cash and study outlook
The company ended the quarter with $190.2 million in cash and marketable securities and expects its cash runway to extend into the second half of 2028. It expects to begin patient dosing in the Strive study in 2026, report initial safety and tolerability data in the first quarter of 2027, and report topline safety and efficacy results from Part 1 in the second half of 2027.
